Enovis (NYSE:ENOV) Releases Earnings Results, Beats Estimates By $0.05 EPS

Enovis (NYSE:ENOV) issued its quarterly earnings results on Thursday. The company reported $0.90 EPS for the quarter, topping analysts’ consensus estimates of $0.85 by $0.05, FiscalAI reports. The company had revenue of $582.78 million for the quarter, compared to analysts’ expectations of $581.84 million. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.Enovis’s revenue was up 3.2% on a year-over-year basis. During the same quarter last year, the business earned $0.79 earnings per share. Enovis updated its FY 2026 guidance to 3.520-3.730 EPS.

Here are the key takeaways from Enovis’ conference call:

• Second-quarter organic sales grew 5%, led by 6% growth in Recon and 3% in PNR. U.S. Recon hips and knees and extremities each grew 8% in the first half, while Nebula, ARG, and the full commercial launch of ARVIS are gaining traction.
• Adjusted gross margin improved 120 basis points on an underlying basis, and adjusted EBITDA margin rose 70 basis points to 17.9%. Management cited favorable product mix, productivity, and Lima integration synergies, and expects continued multi-year margin expansion.
• Free cash flow improved by $27 million year over year to $31 million in the quarter, bringing first-half cash flow slightly positive. The company reaffirmed its target of greater than 25% free-cash-flow conversion for 2026 and aims to reduce leverage below 3x.
• Enovis reaffirmed its 2026 guidance but expects a seasonally weaker-than-usual third quarter because of softer Western European markets and Middle East-related disruption, followed by sales acceleration in the fourth quarter.
• Inflationary pressure from raw materials, freight, distribution, and the Middle East conflict reduced second-quarter results by $2 million and is expected to total a $10 million full-year impact. Management said passing through additional costs remains difficult, particularly in PNR, because of competitive and market pressures.

Enovis Trading Up 1.4%

Shares of ENOV traded up $0.38 during mid-day trading on Friday, reaching $26.68. 2,058,436 shares of the company were exchanged, compared to its average volume of 1,111,529. Enovis has a 52 week low of $19.14 and a 52 week high of $34.28. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.05 and a current ratio of 1.98. The stock has a market capitalization of $1.54 billion, a PE ratio of -1.39 and a beta of 1.34. The business has a 50 day simple moving average of $24.62 and a two-hundred day simple moving average of $23.97.

Insider Buying and Selling

In related news, insider Oliver Engert bought 1,200 shares of Enovis stock in a transaction that occurred on Thursday, June 11th. The shares were acquired at an average cost of $21.62 per share, for a total transaction of $25,944.00. Following the completion of the acquisition, the insider directly owned 51,840 shares of the company’s stock, valued at approximately $1,120,780.80. The trade was a 2.37% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders purchased 4,200 shares of company stock valued at $92,084 in the last quarter. Corporate insiders own 2.90% of the company’s stock.

Institutional Trading of Enovis

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ENOV. California State Teachers Retirement System increased its holdings in shares of Enovis by 1.2% in the 2nd quarter. California State Teachers Retirement System now owns 51,713 shares of the company’s stock worth $1,622,000 after buying an additional 621 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in Enovis by 125.4% in the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after acquiring an additional 707 shares in the last quarter. Empowered Funds LLC grew its position in Enovis by 13.0% in the first quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock worth $249,000 after acquiring an additional 749 shares in the last quarter. Arax Advisory Partners purchased a new position in Enovis in the fourth quarter worth $29,000. Finally, Benjamin Edwards Inc. increased its stake in Enovis by 10.8% in the second quarter. Benjamin Edwards Inc. now owns 15,207 shares of the company’s stock valued at $477,000 after acquiring an additional 1,487 shares during the last quarter. 98.45% of the stock is owned by institutional investors.

More Enovis News

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Enovis reported second-quarter adjusted earnings of $0.90 per share, above the $0.85 analyst consensus and up from $0.79 a year earlier. Revenue of $582.8 million was also slightly ahead of estimates, while sales increased 3.2% year over year. Enovis Q2 Earnings and Revenue Estimates
• Positive Sentiment: Management reaffirmed its full-year 2026 outlook, including revenue of approximately $2.3 billion to $2.4 billion and adjusted EPS guidance of $3.52 to $3.73. Reconstructive sales were a relative bright spot, rising 8% on a reported basis and 6% organically. Enovis Announces Second Quarter 2026 Results
• Positive Sentiment: BTIG Research raised its price target from $39 to $40 and maintained a Buy rating, implying substantial potential upside from recent trading levels. BTIG Research Price Target
• Neutral Sentiment: Wells Fargo lowered its price target modestly from $40 to $39 but retained an Overweight rating, indicating continued long-term confidence despite near-term concerns. Wells Fargo Price Target
• Negative Sentiment: The market reaction was negative because Enovis’ second-quarter performance was characterized as “softer than expected.” Although revenue and EPS exceeded published estimates, investors appear focused on the relatively modest 3% reported sales growth and the lack of an upward guidance revision. Enovis Shares Drop After Second-Quarter Earnings
• Negative Sentiment: Enovis continues to report a deeply negative GAAP net margin, which may reinforce investor concerns about profitability and execution even though adjusted earnings improved. Enovis Q2 2026 Earnings Call Transcript

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ENOV. Evercore set a $32.00 price objective on shares of Enovis in a research note on Monday, July 6th. Wall Street Zen cut shares of Enovis from a “buy” rating to a “hold” rating in a research report on Saturday. William Blair began coverage on shares of Enovis in a report on Friday, April 17th. They set an “outperform” rating for the company. Weiss Ratings upgraded shares of Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 21st. Finally, Zacks Research raised shares of Enovis from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 29th. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $42.00.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.